- Home
- QXO vs INCY Comparison
QXO vs INCY Comparison
Compare QXO & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QXO
- INCY
- Stock Information
- Founded
- QXO 1988
- INCY 1991
- Country
- QXO United States
- INCY United States
- Employees
- QXO N/A
- INCY N/A
- Industry
- QXO EDP Services
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- QXO Technology
- INCY Health Care
- Exchange
- QXO Nasdaq
- INCY Nasdaq
- Market Cap
- QXO 13.2B
- INCY 17.0B
- IPO Year
- QXO N/A
- INCY 1993
- Fundamental
- Price
- QXO $18.49
- INCY $105.57
- Analyst Decision
- QXO Strong Buy
- INCY Buy
- Analyst Count
- QXO 12
- INCY 19
- Target Price
- QXO $33.45
- INCY $89.19
- AVG Volume (30 Days)
- QXO 7.9M
- INCY 2.8M
- Earning Date
- QXO 11-06-2025
- INCY 10-28-2025
- Dividend Yield
- QXO N/A
- INCY N/A
- EPS Growth
- QXO N/A
- INCY 3878.02
- EPS
- QXO N/A
- INCY 5.90
- Revenue
- QXO $4,662,873,000.00
- INCY $4,813,105,000.00
- Revenue This Year
- QXO $12,779.57
- INCY $19.33
- Revenue Next Year
- QXO $56.23
- INCY $10.47
- P/E Ratio
- QXO N/A
- INCY $17.95
- Revenue Growth
- QXO 8107.98
- INCY 18.09
- 52 Week Low
- QXO $11.85
- INCY $53.56
- 52 Week High
- QXO $24.69
- INCY $108.81
- Technical
- Relative Strength Index (RSI)
- QXO 52.29
- INCY 80.92
- Support Level
- QXO $15.50
- INCY $91.16
- Resistance Level
- QXO $18.85
- INCY $106.47
- Average True Range (ATR)
- QXO 0.88
- INCY 4.31
- MACD
- QXO 0.00
- INCY 1.48
- Stochastic Oscillator
- QXO 73.66
- INCY 88.14
About QXO QXO Inc. Common Stock
QXO Inc is a building products distribution company engaged in the distribution of roofing, waterproofing and complementary building products in North America. It offers a full suite of business applications, including ERP, warehouse management, accounting, CRM, and business intelligence solutions.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.